https://www.selleckchem.com/products/og-l002.html
for the early diagnosis and prognosis monitoring of ESCC. CircRNAs can be used as promising molecular biomarkers for the early diagnosis and prognosis monitoring of ESCC.In the phase III RESTORE-IMI 2 study (ClinicalTrials.gov NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all-cause mortality at day 28 and favorable clinical response at the early follow-up visit in adult participants with gram-negative hospital-acquir
Like
Comment
Share
